- Home
- ADNT vs ARVN Comparison
ADNT vs ARVN Comparison
Compare ADNT & ARVN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- ADNT
- ARVN
- Stock Information
- Founded
- ADNT 2016
- ARVN 2015
- Country
- ADNT Ireland
- ARVN United States
- Employees
- ADNT N/A
- ARVN N/A
- Industry
- ADNT Auto Parts:O.E.M.
- ARVN Biotechnology: Pharmaceutical Preparations
- Sector
- ADNT Consumer Discretionary
- ARVN Health Care
- Exchange
- ADNT Nasdaq
- ARVN Nasdaq
- Market Cap
- ADNT 1.5B
- ARVN 1.3B
- IPO Year
- ADNT N/A
- ARVN 2018
- Fundamental
- Price
- ADNT $16.85
- ARVN $20.50
- Analyst Decision
- ADNT Hold
- ARVN Strong Buy
- Analyst Count
- ADNT 9
- ARVN 13
- Target Price
- ADNT $23.50
- ARVN $63.00
- AVG Volume (30 Days)
- ADNT 1.1M
- ARVN 1.1M
- Earning Date
- ADNT 02-05-2025
- ARVN 02-25-2025
- Dividend Yield
- ADNT N/A
- ARVN N/A
- EPS Growth
- ADNT N/A
- ARVN N/A
- EPS
- ADNT 0.20
- ARVN N/A
- Revenue
- ADNT $14,688,000,000.00
- ARVN $161,100,000.00
- Revenue This Year
- ADNT N/A
- ARVN $239.85
- Revenue Next Year
- ADNT $0.91
- ARVN N/A
- P/E Ratio
- ADNT $84.30
- ARVN N/A
- Revenue Growth
- ADNT N/A
- ARVN 1.07
- 52 Week Low
- ADNT $16.28
- ARVN $17.37
- 52 Week High
- ADNT $36.04
- ARVN $53.08
- Technical
- Relative Strength Index (RSI)
- ADNT 33.06
- ARVN 47.17
- Support Level
- ADNT $16.82
- ARVN $18.36
- Resistance Level
- ADNT $17.67
- ARVN $19.74
- Average True Range (ATR)
- ADNT 0.69
- ARVN 1.20
- MACD
- ADNT -0.02
- ARVN 0.22
- Stochastic Oscillator
- ADNT 20.58
- ARVN 86.23
About ADNT Adient plc
Adient began trading Oct. 31, 2016, when Johnson Controls spun off its automotive experience segment. Adient is the leading seating supplier to the industry with about one third of the global market. Its share in China is now nearly 20%, down from about 45%, following the sale of its main joint venture there at the end of fiscal 2021. Unconsolidated revenue from joint ventures was about $3.8 billion in fiscal 2024 and consolidated China revenue was $1.4 billion. The company is headquartered in Ireland but has corporate offices in the Detroit area. Fiscal 2024 (Sept. 30 year-end) consolidated revenue, which excludes joint venture sales, was $14.7 billion.
About ARVN Arvinas Inc.
Arvinas Inc is a United States-based biopharmaceutical company focused on improving the lives of patients suffering from debilitating and life-threatening diseases through the discovery, development and commercialization of therapies that degrade disease-causing proteins.. The company's proprietary Proteolysis-Targeting Chimera (PROTAC), work by inducing the cell's own ubiquitin-proteasome system to target, degrade and remove disease-causing proteins. The group's product candidates are bavdegalutamide, ARV-471 and ARV-766.